Onglyza (Saxagliptin) Dosing Without Renal Assessment
When renal function has not been assessed, you must check renal function before initiating Onglyza (saxagliptin), as the FDA label explicitly requires renal assessment prior to starting therapy. 111
Critical First Step: Assess Renal Function
The FDA prescribing information is unequivocal: assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter 11. This is not optional—it's a mandated safety requirement because:
- Saxagliptin is primarily renally eliminated
- Dose reduction to 2.5 mg daily is required when CrCl ≤50 mL/min (moderate to severe renal impairment or ESRD)
- The standard dose is 2.5 mg or 5 mg daily for normal renal function
Practical Clinical Algorithm
If you cannot assess renal function immediately:
Start with the conservative 2.5 mg daily dose while awaiting renal function results—this is the safe default that covers all renal function levels 11
Obtain serum creatinine and calculate CrCl using Cockcroft-Gault or MDRD formula 1
Adjust dosing based on results:
Why This Matters for Patient Safety
The dose limitation isn't just about efficacy—it's about preventing drug accumulation and potential adverse effects. While recent evidence suggests higher doses may not significantly increase heart failure risk in CKD patients 3, the FDA-mandated approach prioritizes safety through appropriate dose adjustment.
Common pitfall to avoid: Never assume normal renal function in elderly patients, those with long-standing diabetes, hypertension, or cardiovascular disease—these populations have high rates of undiagnosed CKD.
Additional Dosing Considerations
Beyond renal function, also reduce to 2.5 mg daily if the patient is taking strong CYP3A4/5 inhibitors (ketoconazole, clarithromycin, ritonavir, etc.) 111.